1. Home
  2. IKNA vs GOCO Comparison

IKNA vs GOCO Comparison

Compare IKNA & GOCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKNA
  • GOCO
  • Stock Information
  • Founded
  • IKNA 2016
  • GOCO 2001
  • Country
  • IKNA United States
  • GOCO United States
  • Employees
  • IKNA N/A
  • GOCO N/A
  • Industry
  • IKNA Biotechnology: Pharmaceutical Preparations
  • GOCO Specialty Insurers
  • Sector
  • IKNA Health Care
  • GOCO Finance
  • Exchange
  • IKNA Nasdaq
  • GOCO Nasdaq
  • Market Cap
  • IKNA 61.8M
  • GOCO 64.9M
  • IPO Year
  • IKNA 2021
  • GOCO 2020
  • Fundamental
  • Price
  • IKNA $1.35
  • GOCO $5.67
  • Analyst Decision
  • IKNA Strong Buy
  • GOCO Hold
  • Analyst Count
  • IKNA 1
  • GOCO 1
  • Target Price
  • IKNA $4.00
  • GOCO $18.00
  • AVG Volume (30 Days)
  • IKNA 79.7K
  • GOCO 67.1K
  • Earning Date
  • IKNA 08-07-2025
  • GOCO 08-07-2025
  • Dividend Yield
  • IKNA N/A
  • GOCO N/A
  • EPS Growth
  • IKNA N/A
  • GOCO N/A
  • EPS
  • IKNA N/A
  • GOCO N/A
  • Revenue
  • IKNA N/A
  • GOCO $834,266,000.00
  • Revenue This Year
  • IKNA N/A
  • GOCO $8.51
  • Revenue Next Year
  • IKNA N/A
  • GOCO $7.19
  • P/E Ratio
  • IKNA N/A
  • GOCO N/A
  • Revenue Growth
  • IKNA N/A
  • GOCO 13.18
  • 52 Week Low
  • IKNA $0.97
  • GOCO $5.01
  • 52 Week High
  • IKNA $1.94
  • GOCO $21.00
  • Technical
  • Relative Strength Index (RSI)
  • IKNA 53.36
  • GOCO 45.31
  • Support Level
  • IKNA $1.31
  • GOCO $5.45
  • Resistance Level
  • IKNA $1.38
  • GOCO $6.01
  • Average True Range (ATR)
  • IKNA 0.06
  • GOCO 0.47
  • MACD
  • IKNA -0.01
  • GOCO 0.14
  • Stochastic Oscillator
  • IKNA 15.79
  • GOCO 44.63

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

About GOCO GoHealth Inc.

GoHealth Inc is a health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers' peace of mind when making healthcare decisions so consumers can focus on living life. It offers Medicare plans, including, but not limited to, Medicare Advantage, Medicare Supplement and prescription drug plans. Its proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer's specific needs.

Share on Social Networks: